These results indicate that in patients with intermediate to high-risk prostate cancer, PSMA-PET used in conjunction with MRI is more sensitive than mpMRI when staging SVI and the spread of cancer beyond the prostate gland. This evidence concerns the gene FOLH1 and prostate cancer.